TAMPA, Fla., Oct. 30, 2015 /PRNewswire/ — Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa.  The building houses preformulation and formulation development labs and suites, as well as analytical and stability services.  The official ribbon cutting ceremony was attended by Florida Governor Rick Scott, Tampa Mayor Bob Buckhorn and other elected and non-elected officials. 

The new building houses a newly-constructed, state-of-the art formulation lab, as well as the executive headquarters.  Build out plans for a new analytical lab is developing.  The company’s previous headquarters on West Laurel Street in Tampa is transitioning to provide clinical trial and small-scale commercial manufacturing. 

“This year marks a rapid expansion in our service offerings,” says Derek Hennecke, President and CEO.  “In July we integrated with Powdersize because so many of our clients needed industry-leading micronization services.  Now, with this new facility, we will be able to increase capacity throughout the organization.  More capacity means we can be more flexible in dealing with changing client needs and timelines.”

Xcelience is a contract development and manufacturing organization (CDMO) that provides services from preformulation through global clinical supplies packaging and distribution to international pharmaceutical and biotechnology clients for Phases I-IV. 

Since its inception in 2006, Xcelience has grown from one facility with 45 employees to an international CDMO provider, with 7 facilities and over 200 employees.  The company thrives on client-driven innovation.  Xcelience brought the first CDMO Xcelodose to North America, was the first CDMO of its size to offer clinical supply solutions and was the first CDMO of its size to go global by obtaining MHRA approval in the UK in 2013, to name just a few.  The continuous growth throughout the years is a direct reflection of the company’s dedication to its clients and potential clients’ needs.